Episode notes
A shocking new report from the U.S. Federal Trade Commission reveals that the nation’s three largest pharmacy benefit managers have significantly inflated the prices of critical medicines, including those for heart disease, cancer, and HIV. Between 2017 and 2022, these markups at their affiliated pharmacies generated over $7.3 billion in revenue. Antonio Ciaccia, President of 3 Axis Advisors, joined Jeff Hamlin to break down the findings of the FTC report.